title: Clinical Inquiry: Which patients with metabolic syndrome benefit from metformin?
abstract: In patients with metabolic syndrome who are in the highest-risk quartile for progression to diabetes (predicted mean 3-year risk, 60%), metformin, 850 mg twice daily, reduces the absolute risk by about 20% over a 3-year period. Metformin doesn't reduce the incidence in patients at lower risk of progression.
authors.affiliation: Valley Family Medicine Residency, University of Washington at Renton, WA, USA.
authors.forename: Liz
authors.initials: L
authors.lastname: Stover
authors.affiliation: Valley Family Medicine Residency, University of Washington at Renton, WA, USA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Chi
authors.affiliation: Valley Family Medicine Residency, University of Washington at Renton, WA, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Kelsberg
authors.affiliation: University of Washington Health Sciences Library, Seattle, WA, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Safranek
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008687:Metformin / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin